Fuan Pharmaceutical (300194.SZ): Some pharmaceuticals from the subsidiary are intended to be selected for national centralized procurement.

On December 13, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) announced that on December 12, 2024, its wholly-owned subsidiary Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd. and Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Qingyutang and Tianheng Pharmaceutical") participated in the bidding for the tenth national centralized procurement of Pharmaceuticals organized by the National Organization of Pharmaceuticals Centralized Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). After the opening and evaluation of the bids by the Joint Procurement Office, Qingyutang's sodium ampicillin sodium sulbactam (0.75g) and heavy tartrate deoxycorticosterone were assessed.

Gelonghui FinanceDec 13 04:09 ET

fuan pharmaceutical (300194.SZ) received pharmaceutical registration certificates for two pharmaceuticals.

fuan pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qing Yu Tang Pharmaceutical Co., Ltd. (...)

Zhitong FinanceDec 5 03:15 ET

Is Fuan Pharmaceutical (Group) (SZSE:300194) A Risky Investment?

Simply Wall StDec 2 23:38 ET

Fuan Pharmaceutical's Unit to Build API Production Base for 428 Million Yuan

MT NewswiresNov 21 00:14 ET

fuan pharmaceutical (300194.SZ): Bosheng Pharmaceutical plans to invest 0.428 billion yuan to build a green and smart high-end production site for active pharmaceutical ingredient.

On November 20, Gelonghui reported that Fuan Pharmaceutical (300194.SZ) announced that it would hold the first meeting of the sixth board of directors on November 20, 2024, to review and approve the "Proposal for Subsidiary Investment and Construction Projects," agreeing to the investment project by its wholly-owned subsidiary Fuan Pharmaceutical Group Chongqing Boshen Pharmaceutical Co., Ltd. (hereinafter referred to as "Boshen Pharmaceutical") for the construction of a "green, intelligent high-end production facility for active pharmaceutical ingredients." The total investment for the project is expected to be 0.428 billion yuan, constructed with self-owned funds or bank loans. Plans include the construction of a first-class production workshop and a solid storage facility on the company's existing land.

Gelonghui FinanceNov 20 05:36 ET

Fuan Pharmaceutical (300194.SZ): Wholly-owned subsidiary's active pharmaceutical ingredient Benzylpenicillin Sodium approved for market launch.

Gelonghui November 12th | Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary Fuan Pharmaceutical Group's Chongqing Boson Pharmaceutical Co., Ltd. (hereinafter referred to as 'Boson Pharmaceutical') recently received a notice of approval for the marketing application of chemical raw materials issued by the National Medical Products Administration. The active pharmaceutical ingredient is sodium benzoxillin, mainly used for various infections caused by penicillin-resistant Staphylococcus aureus, including sepsis, respiratory tract infections, meningitis, soft tissue infections, etc. It can also be used for mixed infections caused by pyogenic streptococcus or pneumococcus and penicillin-resistant Staphylococcus aureus.

Gelonghui FinanceNov 12 03:29 ET